How This Evidence Evolved
AI in Diabetic Retinopathy Screening
From manual fundus examination to autonomous AI diagnosis
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
External AUC in Chinese community hospitals: 0.983 (0.031)
Referable DR sensitivity 86.72% (95% CI 83.39–90.05%); specificity 96.09% (95% CI 94.14–97.54%)
Current standard of care and ongoing research directions
Landmark Trials in This Story
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
Sensitivity and specificity for referable diabetic retinopathy
Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices
Sensitivity and specificity for more-than-mild diabetic retinopathy
Application of Comprehensive Artificial intelligence Retinal Expert (CARE) system: a national real-world evidence study.
External AUC in Chinese community hospitals: 0.983 (0.031)
Performance of the AIDRScreening system in detecting diabetic retinopathy in the fundus photographs of Chinese patients: a prospective, multicenter, clinical study.
Referable DR sensitivity 86.72% (95% CI 83.39–90.05%); specificity 96.09% (95% CI 94.14–97.54%)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.